Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Oral clofarabine is related to two intravenous chemotherapy drugs used for this disease and
works in two different ways. It affects the development of new cancer cells by blocking two
enzymes that cancer cells need to reproduce. When these enzymes are blocked, the cancer call
can no longer prepare the DNA needed to make new cells. Clofarabine also encourages existing
cancer cells to die by disturbing components within the cancer cell. This causes the release
of a substance that is fatal to the cell.
This trial studies the efficacy of oral clofarabine in the treatment of relapsed non-Hodgkin
lymphomas.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Brigham and Women's Hospital Dana-Farber Cancer Institute Genzyme, a Sanofi Company